Emerald Bioscience (OTCMKTS:EMBI) Shares Up 10.1% – Still a Buy?

Emerald Bioscience Inc. (OTCMKTS:EMBI) rose 10.1% on Wednesday . The stock traded as high as $0.54 and last traded at $0.5194. Approximately 335,342 shares traded hands during trading, a decline of 98% from the average session volume of 14,236,620 shares. The stock had previously closed at $0.4717.

Emerald Bioscience Stock Performance

The firm’s fifty day simple moving average is $0.67. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $139.24 million, a PE ratio of -6.49 and a beta of 0.43.

Emerald Bioscience Company Profile

Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.